The purpose of this study is to establish a new treatment (repetitive transcranial stimulation (rTMS)) for Veterans with stimulant use disorder (SUD). Despite the large public health burden imposed by SUD, there is currently no FDA-approved or widely recognized effective somatic treatment. This placebo controlled study will test the effectiveness of rTMS in the treatment of SUD, and explore biomarkers that may guide patient selection for rTMS treatment and predict treatment response.
Structured Clinical Interview for DSM Disorders (SCID) confirmed diagnosis of SUD, severe
Last use of stimulants >2 and <8 weeks
Stable medication regimen (no change in dose or agents between 2 weeks prior to the start of and throughout the treatment phase of the study)
Stable medical health
Pregnant or lactating female
History of prior adverse reaction to TMS
On medications thought to significantly lower seizure threshold, e.g. clozapine, chlorpromazine, clomipramine, and bupropion > 400mg/day
Seizure disorder or conditions known to substantially increase risk for seizures
VA Office of Research and Development
Lead sponsor
Stanford University
Collaborator